Suven Life Sciences Q1 FY20 results (Apr–Jun 2019) and concall

Suven Life Sciences reported a strong Q1 FY20 in terms of profitability, with EBITDA up 40% and Net Profit up 47% YoY, despite flat revenue. The company provided an optimistic outlook for its CRAMS and Specialty Chemicals segments, revising commercial CRAMS guidance upwards for FY20. Progress on the NCE pipeline, including SUVN-502 data release and SUVN-G3031 trial initiation, along with CAPEX plans and the Rising Pharma acquisition, were key discussion points.